This review summarizes source-supported research findings for the defined tirzepatide molecule and the studied Lilly products. It does not make clinical claims for First Due Biotech material, compounded preparations, salt forms, analogues, or any other non-Lilly material.
Scope and source system
This review draws on the Tirzepatide evidence dossier, its preserved source snapshot, and the verified primary, regulatory, and authoritative sources mapped below. The dossier cutoff is September 3, 2026. The September 6, 2026 verification date records the editorial source-checking pass and does not extend that research cutoff. Status-dependent records, including trial registries, labels, shortage records, and regulatory actions, are reported only as current through the stated cutoff.
The dossier source ledger contains 232 unique rows. Those rows are retained in Literature Index and References as the permanent source-ID system for this compound workspace. The overview and this review cite only the subset needed to support their claims; the remaining rows remain part of the full research inventory rather than public-claim support.
Identity and entity boundaries
Tirzepatide's canonical identity is supported by public substance records: PubChem Compound ID (CID) 156588324; the U.S. Food and Drug Administration/National Center for Advancing Translational Sciences Global Substance Registration System (FDA/NCATS GSRS) Unique Ingredient Identifier (UNII) OYN3CCI6QE; and Kyoto Encyclopedia of Genes and Genomes (KEGG) drug record D11360. These records support the description of tirzepatide as a defined synthetic peptide active moiety rather than a vague product category. P001, P003, P007
The evidence base separates seven entities that cannot be treated as interchangeable:
| Entity | Evidence boundary |
|---|---|
| Tirzepatide molecule / LY3298176 | Chemical identity, receptor pharmacology, and early research evidence. |
| Mounjaro | FDA-approved Lilly finished product with its own label and type 2 diabetes evidence base. |
| Zepbound | FDA-approved Lilly finished product with its own label and weight-management and sleep-apnea evidence base. |
| Investigational Lilly programs | Protocol and trial evidence only for the studied material and population. |
| Compounded tirzepatide | Not interchangeable with approval of a Lilly product; controlled clinical evidence remains unresolved or absent in the dossier. |
| Salt forms, analogues, blends, or similarly described materials | Not established as the same evidence object as the approved active moiety or finished products. |
| First Due Biotech (FDB) research-use-only material | No human clinical evidence is attached to FDB material. |
Pharmacology evidence
Discovery and pharmacology sources support tirzepatide as a unimolecular glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) dual agonist. Coskun et al. describe the discovery-to-proof-of-concept program for LY3298176. Willard et al. characterize the molecule as imbalanced and biased, especially at GLP-1R signaling and internalization readouts. Sun et al. add structural context for dual incretin receptor engagement, while El et al. highlight species and tissue-context limits in islet work. P011, P012, P013, P014
The review conclusion is therefore mechanistic but bounded: dual receptor engagement is well supported; precise quantitative potency comparisons vary by assay; and a direct causal bridge from one signaling property to a specific human outcome has not been established.
Human clinical evidence by domain
Type 2 diabetes
The SURPASS program primarily evaluates surrogate metabolic endpoints in people with type 2 diabetes. SURPASS-2 provides a direct randomized comparison against the semaglutide comparator used in the protocol and reported noninferiority and superiority for mean glycated hemoglobin (HbA1c) change under the trial conditions. Other SURPASS trials compare against placebo or insulin comparators and broaden the population and comparator set. P031, P032, P033, P034, P037, P040, P041
The main limitation is not absence of evidence, but endpoint and attribution discipline. HbA1c and body weight are not interchangeable with clinical-event outcomes, and findings attach to the Lilly product in the studied populations.
Obesity and weight-management research
SURMOUNT-1 supports large average body-weight changes in adults with obesity or overweight without diabetes under trial conditions. SURMOUNT-4 addresses continuation versus withdrawal after a lead-in, and SURMOUNT-5 is a direct active-comparator trial against semaglutide for body-weight and waist outcomes. P051, P061, P064
These studies provide strong evidence for their measured endpoints—principally percentage change in body weight and change in waist circumference—but those measurements do not become universal clinical-outcome claims. Interpretation depends on each trial's prespecified analysis, including whether it estimates outcomes regardless of treatment discontinuation or focuses on continued treatment, how missing measurements are handled, the follow-up period, and the open-label design of the direct comparison.
Cardiovascular, renal, liver, and sleep-apnea evidence
The SURPASS cardiovascular outcomes trial (SURPASS-CVOT) is the central cardiovascular-outcomes trial in the dossier. It compared tirzepatide with dulaglutide in type 2 diabetes with established atherosclerotic cardiovascular disease and met the prespecified noninferiority criterion for the primary cardiovascular composite; superiority was not established in the primary analysis. P085, P086
Renal and cardiorenal findings include biomarker-containing or exploratory composites, including sources tied to SURPASS-4 and SURPASS-CVOT. They support narrower evidence signals rather than broad hard-outcome conclusions. P092, P095
SYNERGY-NASH provides phase 2 evidence for resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening of fibrosis, while fibrosis improvement remains less settled and requires longer, larger confirmation. P098
The SURMOUNT obstructive sleep apnea program (SURMOUNT-OSA) supports apnea-hypopnea index reduction in adults with obesity and moderate-to-severe obstructive sleep apnea and supports the Zepbound label for that specific indication. The evidence does not establish that the sleep-apnea effect is independent of weight change. P103, P138, P140, P153
Safety and tolerability
The safety record is large but product- and population-specific. Labels and trial reports consistently place gastrointestinal events near the center of the tolerability profile. The labels also preserve boxed warning language, contraindications, and warnings related to pancreatitis, gallbladder disease, kidney injury associated with volume depletion, hypersensitivity, hypoglycemia in certain therapy contexts, diabetic-retinopathy complications, delayed gastric emptying, and procedural concerns. P115, P116, P132, P137, P138, P140
The record does not support an unqualified safe/unsafe characterization. Safety findings are comparatively well characterized for the approved Lilly products and studied populations, but they do not transfer to unrelated material quality, excipients, storage, sterility, identity, or preparation practices.
Regulatory and non-Lilly material boundaries
FDA and DailyMed records document distinct Mounjaro and Zepbound product records. Regulatory approval attaches to finished products reviewed under specific applications and labels. It does not attach to a supplier name, a compound page, a salt-form claim, a bulk material listing, or a research-use-only vial. P132, P137, P138, P140, P141, P142
The dossier also includes FDA shortage, compounding, unapproved-drug, and enforcement records. These records are regulatory and supply-chain facts, not evidence that a non-Lilly preparation is clinically equivalent, safe, stable, or effective. P166, P167, P168, P169, P189
The direct non-Lilly evidence located by the dossier is narrow: an analytical study reported an impurity in sampled compounded tirzepatide/vitamin B12 products, while the only identified peer-reviewed human report was an uncontrolled single-author self-experiment. These sources establish neither representative product quality nor clinical equivalence, safety, efficacy, or stability for compounded tirzepatide generally. P192, P195
Evidence limitations and unresolved sources
The dossier's Appendix H lists 133 gap rows. Major limitations include inaccessible supplemental tables, abstract-level publisher access for several high-profile papers, registry records without posted results, sponsor topline items awaiting peer-reviewed or regulatory confirmation, and unresolved compounding/source-quality questions.
Claims depending on unresolved rows remain withheld or pending. Examples include direct assertions about weight-maintenance results for ClinicalTrials.gov record NCT06047548, clinical-event benefit in obesity without diabetes pending SURMOUNT-MMO, quantitative claims about compounded product quality, and direct equivalence or non-equivalence of specific tirzepatide salt forms beyond what the cited regulatory records support.
Research-use notice
This review is educational research documentation. It is not medical advice, legal advice, a dosing guide, an administration guide, a treatment recommendation, or a purchasing recommendation. First Due Biotech products are for laboratory research use only and are not for human consumption.